This website is intended for healthcare professionals. Please do not direct patients to this page.
These resources have been developed by Novartis and are intended for healthcare professionals, to help you get the most out of treating with JAKAVI®.
Real-world treatment evidence
Real-world insights and findings from a UK physician survey on the use of the BSH guidelines for the diagnosis and management of MF
JAKAVI® dosing timeline
A JAKAVI® treatment timeline that can be used during your patient consultations
MF risk stratification with IPSS, DIPSS and DIPSS Plus
JAKAVI® practical management guide
Practical information and advice on using JAKAVI® and managing adverse events
For full product information, please refer to the Summary of Product Characteristics.
These resources have been developed by Novartis and are intended for patients who have been diagnosed with an MPN. These resources will help give patients the confidence and knowledge to discuss their disease and track symptoms effectively. Information provided in these resources should not be considered an alternative to advice from a healthcare professional.
MPN10 Patient Brochure
A brochure specifically designed to help MPN patients record how their symptoms change over time
MPN10 Tracker website
An online tool where patients can record and track changes in symptoms over time
Video: A guide to tracking MPN symptoms with Prof. Claire Harrison
Patient Symptom Guide
A guide to help patients identify and better understand symptoms related to their disease
Understanding MPNs: A Guide
An infographic that explains disease facts and medical terms that patients might encounter during or after diagnosis
MPN Patient Resource webpage
An online hub where patients can download all of these resources and learn more about their disease
JAKAVI® is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. JAKAVI® is also indicated for adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.1
BSH, British Society for Haematology; DIPSS, Dynamic International Prostate Symptom Score; HCP, healthcare professional; IPSS, International Prostate Symptom Score; MF, myelofibrosis; MPN, myeloproliferative neoplasm.
- Novartis Pharmaceuticals UK Ltd. JAKAVI® summary of product characteristics.